Chemotherapy for bronchogenic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and lomustine
P. A. Chahinian, D. J. Arnold, J. M. Cohen, D. P. Purpora, I. S. Jaffrey, A. S. Teirstein, P. A. Kirschner and J. F. Holland
A combination chemotherapy (MACC) consisting of methotrexate, doxorubicin
hydrochloride (Adriamycin), cyclophosphamide, and lomustine (CCNU) was
given to 41 patients with stage III bronchogenic carcinoma, 34 of whom had
disseminated disease. The objective response rate was 46% for all patients
with a median actuarial survival of nine months. Response was seen in all
cell types, including four of ten patients with squamous cell carcinoma,
six of 17 with adenocarcinoma, and six of seven with small-cell anaplastic
carcinoma. Prolongation of survival was apparent for patients of all cell
types. Toxic reactions were moderate and allowed for easy outpatient use.
